Combinations Alliance EOI Calls - MedImmune

We are delighted to announce MedImmune would like to offer two compounds to the Combinations Alliance and the NIHR CRN: Cancer Alliance. 

The two compounds on offer are;

•  MEDI0639 anti-DLL4 mAb

•  MEDI3617 anti-ANG2 mAb

Please refer to the non-confidential data package for further details.

Summary of key dates are the same as those listed for the AstraZeneca call as a joint workshop is planned.